In addition to this, other works have highlighted the use of interleukin-6 (IL-6) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) levels and tumour burden to predict the occurrence of irAEs (32–34). The gene discussed is CTLA4; the disease is neoplasm.